Form 4: Pediatrix Medical Group Executive Reports Significant Equity Grant and Tax-Related Share Withholding

Pediatrix Medical Group's EVP, General Counsel, Chief Administrative Officer, and Secretary, Mary Ann E. Moore, reported the acquisition of 53,004 restricted shares as an annual equity award and the disposition of 6,729 shares for tax withholding.

Summary

• Mary Ann E. Moore, the Executive Vice President, General Counsel, Chief Administrative Officer, and Secretary of Pediatrix Medical Group, Inc. (MD), reported transactions on June 1, 2025.
• She acquired 53,004 shares of common stock as a restricted stock grant under the company's Amended and Restated 2008 Incentive Compensation Plan, with a reported acquisition price of $0.
• These newly acquired restricted shares are subject to a vesting schedule: 25% will vest on June 1, 2026, another 25% on June 1, 2027, and the remaining 50% on June 1, 2028.
• Concurrently, Ms. Moore disposed of 6,729 shares of common stock at a price of $14.15 per share; this disposition was specifically for the payment of taxes upon the vesting of previously granted shares.
• Following these transactions, Mary Ann E. Moore directly beneficially owns 146,613 shares of common stock and indirectly owns 42,227 shares through a trust.

Sentiment

Score: 6

Explanation: The document reports a routine executive equity grant and associated tax withholding. The grant of restricted shares is generally positive for the executive and aligns their interests with the company's long-term performance, while the tax withholding is a standard administrative event.

Positives

• The grant of 53,004 restricted shares to a key executive, Mary Ann E. Moore, aligns her long-term interests with the company's performance and shareholder value.
• The equity award is part of the company's established Amended and Restated 2008 Incentive Compensation Plan, indicating a structured and ongoing approach to executive compensation.

Negatives

• The disposition of 6,729 shares was solely for tax withholding purposes upon the vesting of previous awards, which is a standard and expected administrative event for equity compensation and does not represent a negative operational or financial outcome.

Risks

• The ultimate value of the restricted shares granted is subject to the future performance and market price fluctuations of Pediatrix Medical Group's common stock until they fully vest.
• The vesting of the restricted shares is contingent upon the executive's continued employment with the company, as per the terms of the Incentive Compensation Plan.

Future Outlook

The multi-year vesting schedule for the restricted shares, extending until June 1, 2028, signifies a long-term incentive structure for the executive, aligning her future performance and commitment with the company's sustained success.

Management Comments

• "Restricted shares granted pursuant to the Issuer's Amended and Restated 2008 Incentive Compensation Plan, in connection with an annual equity award."
• "Represents 6,729 restricted shares withheld for payment of taxes upon vesting of shares."
• "The reporting person and her spouse are trustees of the trust that holds the reported securities. The reporting person disclaims beneficial interest of the reported securities except to the extent of her pecuniary interest therein."

Industry Context

The use of restricted stock awards as a form of executive compensation is a prevalent practice across various industries, including healthcare services, serving as a mechanism to incentivize long-term performance, align management interests with shareholders, and retain key talent.

Comparison to Industry Standards

• NA

Related Party Transactions

• Mary Ann E. Moore and her spouse serve as trustees of the trust that holds 42,227 shares of Pediatrix Medical Group common stock, representing an indirect beneficial ownership interest.

Stakeholder Impact

• Shareholders: The grant of restricted shares to a key executive aligns management's interests with long-term shareholder value, potentially fostering better performance and retention of critical talent. The tax withholding transaction has no direct impact on shareholder value.
• Employees: This filing specifically pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy for senior leadership.

Next Steps

• 25% of the granted restricted shares will vest on June 1, 2026.
• Another 25% of the granted restricted shares will vest on June 1, 2027.
• The remaining 50% of the granted restricted shares will vest on June 1, 2028.

Key Dates

Keywords

Pediatrix Medical Group, MD, SEC Form 4, Insider Transaction, Executive Compensation, Restricted Stock Unit, Equity Award, Share Grant, Tax Withholding, Beneficial Ownership